Polycystic ovary syndrome (PCOS) affects 8–13% of women of reproductive age by Rotterdam criteria and is the most common endocrine disorder in this population. Its defining features — hyperandrogenism (elevated testosterone causing acne, hirsutism, hair thinning), ovulatory dysfunction (irregular or absent periods), and polycystic ovarian morphology — are downstream of a central metabolic defect: insulin resistance, present in an estimated 70–80% of PCOS patients regardless of BMI.
The insulin resistance in PCOS is not simply a consequence of obesity — it is a primary defect present even in lean PCOS women (with a unique post-receptor serine phosphorylation abnormality of the insulin receptor). Elevated insulin directly stimulates ovarian theca cells to produce androgens and suppresses hepatic SHBG production, increasing free testosterone availability. This mechanistic link between insulin resistance and androgen excess is why GLP-1 receptor agonists — which reduce insulin resistance through multiple pathways — are increasingly recognized as a well-targeted PCOS treatment despite being off-label for this indication.
| Treatment | Mechanism | Weight | Androgens | Ovulation | Fertility Safety |
|---|---|---|---|---|---|
| Metformin | AMPK; reduces hepatic glucose; insulin sensitization | Modest -2–3kg | Moderate T reduction; SHBG increase | Improves rate; lower than GLP-1 | Can continue through 1st trimester (many guidelines) |
| Semaglutide / GLP-1 | GLP-1R agonism; insulin sensitization; satiety; possible direct ovarian effects | Substantial -7–15% | -30% T; +40% SHBG | 43% vs 17% placebo (Elkind-Hirsch) | STOP ≥2 months before conception — no human pregnancy safety data |
| Inositol (myo + D-chiro) | Insulin signaling second messenger | Modest benefit | Moderate androgen reduction | Improves ovulation and cycle regularity | Safe throughout pregnancy and conception |
| Spironolactone | Androgen receptor blocker | Neutral / mild loss | Best for hirsutism/acne; direct blockade | Does not restore ovulation | Contraindicated in pregnancy (feminizes male fetus) |
| OCP | Suppresses LH → reduces ovarian androgen production; increases SHBG | Variable | Best for acne/hirsutism management | Suppresses ovulation — not for conception | Stop before trying to conceive |
Best candidates for GLP-1 in PCOS: Obese or overweight PCOS (BMI ≥27) with failed/intolerant metformin; PCOS + pre-diabetes or metabolic syndrome; women seeking weight loss as a primary goal alongside hormonal improvement; women not actively trying to conceive in the near term; women who have responded poorly to metformin for androgen/cycle control.
Who should avoid GLP-1 for PCOS: Actively trying to conceive — GLP-1 receptors expressed in placenta; rodent teratogenicity data exists; human pregnancy safety unknown; stop ≥2 months before conception attempts; lean PCOS (BMI <25) — less evidence of meaningful benefit; primary goal is fertility urgently — clomiphene/letrozole, inositol, or metformin have stronger fertility-specific evidence and better safety profiles during conception.
Practical combination approach: GLP-1 + myo-inositol 2g + D-chiro-inositol 50mg daily: mechanistically complementary (inositol acts as insulin signaling second messenger; GLP-1 improves upstream receptor sensitivity); inositol is pregnancy-safe — can be continued through conception attempts, while GLP-1 is stopped 2 months prior; berberine 500mg 2–3×/day can serve as a lower-cost adjunct with AMPK activation and modest insulin sensitization; the combination of GLP-1 (while not trying to conceive) then switch to inositol + berberine + metformin (when trying to conceive) is a clinically reasonable sequencing approach.
Monitoring markers in PCOS on GLP-1: Menstrual cycle regularity (early response marker — often improves at 8–12 weeks); total and free testosterone + SHBG at 3 and 6 months; fasting insulin and HOMA-IR; weight and waist circumference; acne and modified Ferriman-Gallwey hirsutism score if primary concerns; standard GLP-1 tolerability monitoring; at plateau: reassess whether goals achieved warrant continued use vs. transitioning to fertility-safe alternatives.